Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Go back to Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 30.55 +0.60 (2.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.95 | 52 Week High | $5.17 | |||
| Open | $30.02 | 52 Week Low | $0.94 | |||
| Day High | $30.60 | P/E | N/A | |||
| Day Low | $29.80 | EPS | $0.00 | |||
| Volume | 906,844 | |||||
